Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No need for a FB Live Presenation---see him here talk about how to make money.....it's a packed house.
And funny how this press release was for Latin American @ $150MM and another release earlier this month was for the same organization but in China for $150MM. Also on the Zhittya website they have similar deals
Press Releases:
January 4, 2016: Zhittya Regenerative Medicine Inc., Signs a $150 Million Dollar Marketing Partnership
January 12, 2016: Derma Healing BioPharmaceuticals Inc. Signs a $150 Million Marketing Partnership
January 17, 2015: Zhittya Regenerative Medicine Inc. Signs its Third Partnership to Market its Biological Drugs in the Middle East
What's interesting is the press releases on the website are not linked to anything so one cannot learn more about these extraordinary deals and all at $150MM ---fantastic.
I may be wrong but I thought the company's focus is developing products for out licensing opportunities. In other words VT develops a product and allows pharma A to licenses it at it's current stage of development or pay VT a fee to continue developing it and pay milestone payments as VT meets predetermined goals---and if launched, Pharma A pays VT royalties. There are many different scenarios for VT to get paid and paid well without having to commercialize the developed products. All good stuff. I provided a link to another company that uses that same business model and they are are doing very well.
Here it is: https://www.ligand.com/about/overview
Anyone on the board here know whatever happened to Thomas J. Stegmann? Was he a DM cronie or did he get screwed in this debacle too? If the latter, I wonder if it would ever be possible for him to come back and advise for CVBT at a minimum? Not sure what the general feeling is on this board but it seemed in the early days he was a great asset to the company and wonderful ambassador for this cause.
I received this alert this past week. Am I correct in thinking David Riggi is(was) the attorney representing the party suing CVBT?
Order Granting Motion To Withdraw As Attorney of Record (Related document(s) [194]) DAVID A RIGGI terminated from the case. (filed: 11/25/2019)
Yep might kill the mood.
Another example of a pre-clinical company getting bought for nearly $1B. This company was bought for it's technology or platform if you will. This is what I believe to be the value of CVBT, the technology used to create lifesaving drugs. AS pipelines dry up, companies like CVBT will be bought to offer hope in creating new drugs and beefing up the pipeline of large pharma. Just need the legal obstacles to get cleared up first.
https://www.fiercebiotech.com/biotech/vertex-plunks-down-950m-for-stem-cell-player-semma-therapeutics?mkt_tok=eyJpIjoiWm1ZNU5XTmtaRE0xTkRBeCIsInQiOiJKWmpKM1Z3b2FFOVwvaXdPRUdQbTRqQ3pFdStadG5zblR4UGs3WjZCbmlKWXA4TkJXd2pUUUNhQ1RFUklDdUgybncwRlF3ZlVCejErbEUzbE1zYjZTT2VERFR0bzZaZUdRSTRRY3doMm9xSjZsbzNBaFJsa2ROR3ZcL1V3d0NSenJYIn0%3D&mrkid=41937656
I agree Beagle.
I would also like to add that even if CVBT stock was trading and the clinical trials were on track----we would still experience many periods of silence. My point is, even the well positioned Biotechs of the world aren't always posting information and providing continuous updates for many reasons but sometimes its simply because there isn't anything to report. We also have to understand that to develop this technology and the resulting products takes time ( years) ----which means we have to be patient.
Like you, I don't understand the negative posts ---we can't lose anymore money so not sure what good it is doing. The way I look at it, you can't get hurt falling out of a basement window. We've hit bottom....no where to go but up. And if it doesn't happen? Well I've already came to terms with that I may not see my money. So reading the negative posts doesn't sway me one bit.
Not sure if this is what you were talking about:
https://www.ligand.com/portfolio-summary/partners-and-licenses
https://www.ligand.com/portfolio-summary/royalty-table
https://www.ligand.com/portfolio-summary/portfolio
Awesome!
Thanks for the for the info. Did your contact happen to mention what Phase study it was for PK? Just curious.
What I find to be more promising, if I understood CVBT Management correctly, is that the company intends to license out these programs(products) once they are developed successfully. CVBT can make tons of money simply licensing out the products to bigger pharma who would then have the responsibility of commercializing. Maybe in time they launch their own but to launch a drug now a days is very expensive and can be risky when you are talking about a new novel therapy. Market Access and pricing become the biggest issues.
Interesting find ( I think) - CVBT's new CMO, Dr. Sherman, comes from Okyanos a regenerative medicine firm that is part of the Black Beret Life Science's portfolio. Not sure exactly, but it seems that Black Beret is a holding company of some sort? ---and I'm wondering if they are providing any financial backing??? I'm not trying to start any crazy goose chase, it's just something I found.
https://www.bbls.net/portfolio/okyanos/
Dude you need to relax on age, industry experience, and work locations. I work with small/mid-size biotechs from the vendor side and I can tell you that it is not uncommon to find folks working in senior level positions that match your big 3 criteria.
Age. Age never concerns anyone so not sure why you are making that a big deal. Some people work well into their 70's or later because of the mission they believe they are on to produce live saving therapies. I am not worried about that.
Industry experience. I call on folks every day who are key decision makers for their respective companies who do not have a huge industry (biotech/healthcare) background. They do have the right experience or expertise in managing the area they were hired for. Are you really hung up on our CEO not having a college degree? Ever hear of Bill Gates? He doesn't have one and he seems to be doing okay. What's more, he and his wife started a fund that supports vaccine development in 3rd world countries---and with no industry experience. How about Don Rumsfeld, ever hear of him? He was a CEO of a Pharma company and then later the Chairman of Gilead Sciences at one point in time...he was a Political Science Major. Get off the no industry experience that simply doesn't fly.
Location. I really don't need to even make a point about that. Very ignorant to think a company can't be ran by a remote team. I can tell you first hand that I have many clients who work remotely and are still able to effectively mange their workload.
As I mentioned in my previous post, it is not uncommon to have consultants managed key aspects of a company like financing, and/or research. Most consultants won't say in their "linkedin" profile that they work for just one company if they represent others. Many times these consultants are brought on board to work part time due to workload requirements----and many times these consultants become full time employees of the company if/when the company takes off. Too many scenarios to describe.
All this being said, I have no idea if this company will pull out a tiger woods-like comeback, but I sure hope so for the good of many and the detriment to a few.
I'll tell you who would invest in this company, those who value the IP, the patents, the platform. If Wallen's team doesn't pull this off, the value of these patents are worth quite a bit I'm sure. I'm not an expert on this but I would think if CVBT found itself in a no win situation, they could at least sell their assets or be acquired. I don't see that helping us unfortunately ( unless we are relisted when this happens) but I'm simply replying to Wallhall's question about who would invest in this company.
On the flip-side, if we get this sucker up and running, the assets will be worth more as they enter later stages of development and hopefully by that time CVBT is relisted.
It's all speculation but these are the two scenarios that I'm focused on.
By the way, using words like "Turmoil" to try and create panic is falling on deaf ears to those of us who have been involved with this company from early on. We've been through "Turmoil" at the top of CVBT already, we are now hardened CVBT Veteran Investors who can tolerate more than just words and looking forward to seeing this company produce lifesaving therapies. First steps are to get a solid management team in place. Then get the trials back on track. Hopefully, simultaneously, we get relisted. All this will take time and patience on our parts. But because things go silent for a while it does not mean there is "Turmoil" at the top. :)
Mike Flaa was a consultant and in my opinion, kept things moving during this transition from old CVBT Mgmt to Wallen's team. It is not uncommon to see consultant's leave their position once the company is ready to enter the next stage of development---usually because the company needs a more tenured Biotech professional who knows his/her way around. This is not a knock against Flaa, but just a reality. By the way I see Flaa is still on the BOD, why would he leave the company but stay on the board if things were so bad?
As for Ori Ben-Yehuda, I see on LinkedIn he's head of a clinical trial center and perhaps his role with CVBT was temporary to help guide them on getting thier trials back on track---I see CVBT has another CMO on board with a great resume.
This is all speculation but I believe "based on my experience" both were consulting and have left to allow more experienced folks come on board and take this company to the next level. Just my opinion.
Don't get me wrong I'd love to see this thing take off --I've been a shareholder since 06 and like most on this board, have been on a crazy ride with this company and would love nothing more to see these products get approved and patients' lives improved.Given that many of these types of biotechs ( emerging/small/midsize) are my clients on the West Coast, I've seen 4 types of scenarios playout, 1) company licenses out technology or promising programs to large pharma 2) large pharma gives CVBT money upfront and milestone payments( or royalties) for specific achievements in a product's development including clinical trial success, FDA/European approval, launching a product successfully, and meeting predetermined sales targets or 3) small pharma gets bought by large pharma or merged with another company. 4) CVBT goes it alone which is possible but not likely in my opinion. All of which are usually positive for shareholders.
One of the higher buyouts last year was Celgene and BMS worth 75B. But if we take that out of the equation ( because CVBT is not the size of Celgene)...I'm seeing buyouts between $300m - 6B but I doubt the avg was 12B.
Try this link: https://index.co/market/biotechnology/acquisitions